Dropout rate due to side effects

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI

Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side effects compared to placebo and low-dose SSRI, though the increased side-effect burden was somewhat c

Effect: adverse; ARD=0.07, NNH=14.3 (high vs placebo); ARD=0.05, NNH=16.7 (high vs low dose); CI: 95% CI: 0.03-0.11, NNH 95% CI: 9.9-50.0 (vs placebo); 95% CI